Study type

Study topic

Disease /health condition

Study type

Non-interventional study

Scope of the study

Other

If ‘other’, further details on the scope of the study

To describe clinical characteristics of subjects using Repatha

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Cohort
Other

Non-interventional study design, other

Multicountry, observational, serial chart review
Study drug and medical condition

Medical condition to be studied

Hyperlipidaemia
Population studied

Short description of the study population

Patients receiving Repatha® as part of routine clinical management of their hyperlipidaemia.

All inclusion criteria need to be met, as follows:
• Adults (≥ 18 years)
• Provided informed consent if applicable according to local requirements
• Initiated on Repatha® at physician’s discretion, after 1st August 2015
• Received at least one dose of Repatha®

Exclusion Criteria
If at least one exclusion criterion is met, subject is not eligible for participation in the study, as follows:
• Enrolled in an interventional study of PCSK9 inhibitor within 12 weeks prior to initiation of Repatha®
• Received commercially available PCSK9 inhibitor within 12 weeks prior to initiation of Repatha®

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

2000
Study design details

Main study objective

To ascertain the clinical characteristics of patients who are prescribed Repatha® in the post-launch period, and how their treatment is managed

Outcomes

To describe the clinical characteristic of subjects at initiation of Repatha®, To describe LDL-C and other cholesterol concentrations over time To described treatment patterns of use of Repatha® over time To describe treatment patterns of use of other lipid modifying therapies over time To describe Health Resource Utilisation components, including hospitalisations and physician visits

Data analysis plan

All summaries of the data will be descriptive in nature. For categorical variables the frequency and percentage, with 95% confidence interval, will be given. Summary statistics for continuous variables will include the number of subjects, mean, median, standard deviation or standard error, 25th percentile (Q1), 75th percentile (Q3), minimum, and maximum. Regarding the primary endpoints, summaries displaying frequency and percentage, with 95% confidence intervals will be presented for FH status, CV history and diabetic status at the time of initiation of Repatha®, while summary statistics displaying the number of subjects, mean, median, standard deviation, 25th percentile (Q1), 75th percentile (Q3), minimum, and maximum will be presented for LDL-C at the time of initiation of Repatha®. The primary intention is to analyse data for each country separately, but the final analysis will also be conducted for all countries pooled.
Documents
Study results
English (147.65 KB - PDF)View document